The Medical Letter on Drugs and Therapeutics
Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a fixed-dose combination of the angiotensin receptor blocker (ARB) azilsartan and the thiazide-like diuretic chlorthalidone as Edarbyclor (Takeda) for treatment of hypertension.

THE ARB — Azilsartan medoxomil (Edarbi) was the eighth ARB to become available in the US for treatment of hypertension.1 The results of some studies have suggested that azilsartan might be slightly more effective than some other ARBs in lowering blood pressure.2

THE DIURETIC — Chlorthalidone is 1.5-2 times more potent than hydrochlorothiazide (HCTZ) and has a longer duration of action that persists throughout the nighttime hours.3 In a study that measured 24-hour ambulatory blood pressure, chlorthalidone 25 mg was more effective in lowering blood pressure than HCTZ 50 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Edarbyclor: An ARB Chlorthalidone Combination for Hypertension
Article code: 1385a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian